Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Axsome Therapeutics (AXSM) Work In Process (2022 - 2026)

Axsome Therapeutics' Work In Process history spans 5 years, with the latest figure at $15.5 million for Q1 2026.

  • On a quarterly basis, Work In Process rose 127.41% to $15.5 million in Q1 2026 year-over-year; TTM through Mar 2026 was $15.5 million, a 127.41% increase, with the full-year FY2025 number at $17.8 million, up 130.95% from a year prior.
  • Work In Process hit $15.5 million in Q1 2026 for Axsome Therapeutics, down from $17.8 million in the prior quarter.
  • Over the last five years, Work In Process for AXSM hit a ceiling of $17.8 million in Q4 2025 and a floor of $6.8 million in Q1 2025.
  • Historically, Work In Process has averaged $11.0 million across 5 years, with a median of $10.5 million in 2024.
  • The widest YoY moves for Work In Process: up 130.95% in 2025, down 37.64% in 2025.
  • Tracing AXSM's Work In Process over 5 years: stood at $14.0 million in 2022, then decreased by 26.34% to $10.3 million in 2023, then decreased by 24.92% to $7.7 million in 2024, then surged by 130.95% to $17.8 million in 2025, then decreased by 13.34% to $15.5 million in 2026.
  • Business Quant data shows Work In Process for AXSM at $15.5 million in Q1 2026, $17.8 million in Q4 2025, and $12.9 million in Q3 2025.